Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-8722
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond ; volume:14 ; number:1 ; day:23 ; month:7 ; year:2021 ; pages:1-18 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (23.7.2021), 1-18, 12.2021

Creator
Su, Christopher T.
Ye, J. Christine
Contributor
SpringerLink (Online service)

DOI
10.1186/s13045-021-01109-y
URN
urn:nbn:de:101:1-2021102322272190656537
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Su, Christopher T.
  • Ye, J. Christine
  • SpringerLink (Online service)

Other Objects (12)

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

A suggestion to improve the results of “Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma”

A suggestion to improve the results of “Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma”

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma

Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma

Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature

Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Related objects